ONCOLYTICS BIOTECH INC ONCY
We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.
Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA ("dsRNA") virus commonly found in environmental waters. Pelareorep has shown promising results in changing the tumor microenvironment ("TME"). This creates a more immunologically favorable TME, making the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors ("CPIs"), and other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and RAS or CDK4/6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and upregulates the expression of PD-1/PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D | $13.3M | $15.4M | — | — | — | — | — | — | — |
| SG&A | $15.4M | $10.1M | — | — | — | — | — | — | — |
| Total operating expenses | $28.7M | $25.5M | — | — | — | — | — | — | — |
| Operating income | -$28.7M | -$25.5M | — | — | — | — | — | — | — |
| Pre-tax income | -$28.7M | -$22.7M | — | — | — | — | — | — | — |
| Income tax | $79.0K | $95.0K | — | — | — | — | — | — | — |
| Net income | -$28.8M | -$22.8M | — | — | — | — | — | — | — |
| EPS, basic | -0.30 | -0.30 | — | — | — | — | — | — | — |
| EPS, diluted | -0.30 | -0.30 | — | — | — | — | — | — | — |
| Shares, diluted (wtd. avg.) | 95.9M | 76.5M | — | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.2M | $11.1M | $26.4M | — | — | — | — | — | — |
| Total current assets | $6.8M | $12.4M | — | — | — | — | — | — | — |
| Property, plant and equipment | $228.0K | $286.0K | — | — | — | — | — | — | — |
| Total assets | $7.6M | $13.4M | — | — | — | — | — | — | — |
| Accounts payable | $3.5M | $756.0K | — | — | — | — | — | — | — |
| Total current liabilities | $6.1M | $4.9M | — | — | — | — | — | — | — |
| Total liabilities | $11.4M | $10.1M | — | — | — | — | — | — | — |
| Retained earnings | -$429.5M | -$400.7M | — | — | — | — | — | — | — |
| Total equity | -$3.8M | $3.3M | $19.6M | — | — | — | — | — | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.1M | -$19.9M | — | — | — | — | — | — | — |
| Depreciation and amortisation | $70.0K | $87.0K | — | — | — | — | — | — | — |
| Stock-based compensation | $3.1M | $2.0M | — | — | — | — | — | — | — |
| Capital expenditure | $6.0K | $174.0K | — | — | — | — | — | — | — |
| Investing cash flow | -$6.0K | -$174.0K | — | — | — | — | — | — | — |
| Financing cash flow | $14.1M | $5.0M | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001129928-26-000020.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | — | — | — | — | — | — | -$22.8M | -$28.8M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Other event Item 8.01
- Other event Item 8.01
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |